



## Posters from Zai Lab, GSK/Tesaro, MacroGenics and Novocure will be presented at the ESMO Congress 2019

July 31, 2019

Posters from Zai Lab, GSK/Tesaro, MacroGenics and Novocure will be presented at the upcoming European Society for Medical Oncology (ESMO) congress 2019, to be held Sept.27- Oct. 1, 2019, in Barcelona, Spain.

- **NVCR Poster:** 1852P - Effects of Tumor Treating Fields (TTFields; 150 kHz) and Cisplatin or Pemetrexed Combination Therapy on Mesothelioma cells In Vitro and In Vivo, 9/28; 12:00-13:00, Poster area (Hall 4)
- **GSK/Tesaro Poster:** 55P - Synergistic activity between niraparib and chemotherapy in colorectal cancer: molecular determinants from a preclinical model, 9/28; 12:00 13:00, Poster area (Hall 4)
- **GSK/Tesaro Poster:** 211P - Clinical Confirmation of Higher Exposure to Niraparib in Tumor vs Plasma in Patients With Breast Cancer, 9/29; 12:00 13:00, Poster area (Hall 4)
- **GSK/Tesaro Poster:** 1006P - Niraparib initial dose and its' management in patients with recurrent high-grade serous ovarian cancer, 9/29; 12:00 13:00, Poster area (Hall 4)
- **ZLAB Poster:** 1004P - A Prospective Evaluation of Tolerability of Niraparib Dosing Based on Baseline Body Weight (BW) and Platelet (plt) Count: Blinded Pooled Interim Safety Data from the NORA Study, 9/29; 12:00 13:00, Poster area (Hall 4)
- **MGNX Poster Discussion:** 1188PD - Margetuximab (M) + pembrolizumab (P) for treatment of patients (pts) with HER2+ gastroesophageal adenocarcinoma (GEA) post-trastuzumab (T): Survival analysis, 9/30; 08:45 09:45, Malaga Auditorium
- **MGNX Poster Discussion:** 1189PD - Determinants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T), 9/30; 08:45 09:45, Malaga Auditorium
- **MGNX Poster:** 123P - Evaluation of tumor microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA), 9/30; 12:00 13:00, Poster Area (Hall 4)
- **NVCR Poster:** 1976P - General Methodology to Optimize Tumor Treating Fields Delivery Utilizing Numerical Simulations, 9/30; 12:00 13:00, Poster area (Hall 4)
- **GSK/Tesaro Poster:** 1412P - Analytical performance of the Resolution-HRD plasma assay used to identify mCRPC patients with biallelic disruption of DNA repair genes for treatment with niraparib, 9/30; 12:00 13:00, Poster area (Hall 4)